Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Revenue | 4.18B | 7.3% |
| Gross Profit | 2.1B | 12% |
| Cost of Revenue | 2.07B | 3% |
| Operating expense | 1.2B | 11.4% |
| Net Income | 282M | 31.8% |
| EBITDA | 455M | 40.4% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 40.1B | 4.5% |
| Total Liabilities | 21.4B | 33.3% |
| Total Equity | 6.83B | 9.1% |
| Shares Outstanding | 1.16B | 0.2% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | 227M | 316.2% |
| Cash from financing | 6M | 100.3% |
EPS
Financial Highlights for Teva Pharmaceutical in Q2 '25
Teva Pharmaceutical reported a revenue of 4.18B, which is a 7.3% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 2.1B, marking a 12% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 2.07B, a 3% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 1.2B, showing a -11.4% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 282M, showing a 31.8% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 455M, showing a -40.4% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Teva Pharmaceutical with growth in revenue, gross profit, and net income. A decline in EBITDA signals potential operational challenges or increased costs.
